Bactericidal effect of tomatidine-tobramycin combination against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa is enhanced by interspecific small-molecule interactions

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7458-7464

  Boulanger, Simon ^a   Mitchell, Gabriel ^a   Bouarab, Kamal ^a   Marsault, Éric ^b   Cantin, André ^b   Frost, Eric H ^b   Déziel, Eric ^c   Malouin, François ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 HEPTYL 4 HYDROXYQUINOLINE 1 OXIDE; ALKALOID; ANTIBIOTIC AGENT; CIPROFLOXACIN; ERYTHROMYCIN; LASA PROTEASE; OXACILLIN; PROTEINASE; TOBRAMYCIN; TOMATIDINE; UNCLASSIFIED DRUG; 2-(N-HEPTYL)-4-HYDROXYQUINOLINE N-OXIDE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; LASA PROTEIN, PSEUDOMONAS AERUGINOSA; LASR PROTEIN, PSEUDOMONAS AERUGINOSA; METALLOPROTEINASE; QUINOLINOL DERIVATIVE; TOMATINE; TRANSACTIVATOR PROTEIN; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL KINETICS; COCULTURE; CONTROLLED STUDY; CYSTIC FIBROSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COCULTURE TECHNIQUES; DRUG SYNERGISM; HYDROXYQUINOLINES; METALLOPROTEASES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; TOBRAMYCIN; TOMATINE; TRANS-ACTIVATORS; VIRULENCE FACTORS;

EID: 84954507006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01711-15     Document Type: Article

References (50)

1. Riordan JR. 2008. CFTR function and prospects for therapy. Annu Rev Biochem 77:701-726. http://dx.doi.org/10.1146/annurev.biochem.75.103004.142532.
2. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. http://dx.doi.org/10.1128 /CMR.15.2.194-222.2002.
3. Cystic Fibrosis Foundation USA. 2013. Cystic fibrosis patient registry, 2012 annual data report. Cystic Fibrosis Foundation USA, Bethesda, MD.
4. Novick RP. 2003. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48:1429-1449. http://dx.doi.org/10.1046/j.1365-2958.2003.03526.x.
5. Gellatly SL, Hancock RE. 2013. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159-173. http://dx.doi.org/10.1111/2049-632X.12033.
6. Otto M. 2012. MRSA virulence and spread. Cell Microbiol 14:1513-1521. http://dx.doi.org/10.1111/j.1462-5822.2012.01832.x.
7. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. 2010. Association between respiratory tract methicillinresistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303: 2386-2393. http://dx.doi.org/10.1001/jama.2010.791.
8. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. 2008. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV 1 decline in cystic fibrosis. Am J Respir Crit Care Med 178:814-821. http://dx.doi.org/10.1164/rccm.200802-327OC.
9. Lynch SV, Bruce KD. 2013. The cystic fibrosis airway microbiome. Cold Spring Harb Perspect Med 3:a009738. http://dx.doi.org/10.1101 /cshperspect.a009738.
10. Surette MG. 2014. The cystic fibrosis lung microbiome. Ann Am Thorac Soc 11(Suppl 1):S61-S65. http://dx.doi.org/10.1513/AnnalsATS.201306-159MG.
11. Voggu L, Schlag S, Biswas R, Rosenstein R, Rausch C, Götz F. 2006. Microevolution of cytochrome bd oxidase in staphylococci and its implication in resistance to respiratory toxins released by Pseudomonas. J Bacteriol 188:8079-8086. http://dx.doi.org/10.1128/JB.00858-06.
12. Kessler E, Safrin M, Olson JC, Ohman DE. 1993. Secreted LasA of Pseudomonas aeruginosa is a staphylolytic protease. J Biol Chem 268:7503-7508.
13. Mitchell G, Séguin DL, Asselin AE, Déziel E, Cantin AM, Frost EH, Michaud S, Malouin F. 2010. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide. BMC Microbiol 10:33. http://dx.doi.org/10.1186/1471-2180-10-33.
14. Biswas L, Biswas R, Schlag M, Bertram R, Götz F. 2009. Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl Environ Microbiol 75:6910-6912. http://dx.doi.org/10.1128/AEM.01211-09.
15. Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI. 2006. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 103:19890-19895. http://dx.doi.org/10.1073/pnas.0606756104.
16. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295-305. http://dx.doi.org/10.1038/nrmicro1384.
17. Fugère A, Lalonde Seguin D, Mitchell G, Déziel E, Dekimpe V, Cantin AM, Frost E, Malouin F. 2014. Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. PLoS One 9:e86705. http://dx.doi.org/10.1371/journal.pone.0086705.
18. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776.
19. Ceri H, Olson ME, Turner RJ. 2010. Needed, new paradigms in antibiotic development. Expert Opin Pharmacother 11:1233-1237. http://dx.doi.org/10.1517/14656561003724747.
20. Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel PR, Serreau R, Dusser D, Poyart C, Coste J. 2013. Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. J Cyst Fibros 12:497-503. http://dx.doi.org/10.1016/j.jcf.2012.12.003.
21. González-Lamothe R, Mitchell G, Gattuso M, Diarra MS, Malouin F, Bouarab K. 2009. Plant antimicrobial agents and their effects on plant and human pathogens. Int J Mol Sci 10:3400-3419. http://dx.doi.org/10.3390 /ijms10083400.
22. Martin-Hernandez AM, Dufresne M, Hugouvieux V, Melton R, Osbourn A. 2000. Effects of targeted replacement of the tomatinase gene on the interaction of Septoria lycopersici with tomato plants. Mol Plant Microbe Interact 13:1301-1311. http://dx.doi.org/10.1094/MPMI.2000.13.12.1301.
23. Choi SH, Ahn JB, Kozukue N, Kim HJ, Nishitani Y, Zhang L, Mizuno M, Levin CE, Friedman M. 2012. Structure-activity relationships of α-, β1-, γ-, and δ-tomatine and tomatidine against human breast (MDA-MB-231), gastric (KATO-III), and prostate (PC3) cancer cells. J Agric Food Chem 60:3891-3899. http://dx.doi.org/10.1021/jf3003027.
24. Huang H, Chen S, Van Doren J, Li D, Farichon C, He Y, Zhang Q, Zhang K, Conney AH, Goodin S, Du Z, Zheng X. 2015. α-Tomatine inhibits growth and induces apoptosis in HL-60 human myeloid leukemia cells. Mol Med Rep 11:4573-4578.
25. Mitchell G, Lafrance M, Boulanger S, Séguin DL, Guay I, Gattuso M, Marsault E, Bouarab K, Malouin F. 2012. Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression. J Antimicrob Chemother 67:559-568. http://dx.doi.org/10.1093/jac/dkr510.
26. Mitchell G, Gattuso M, Grondin G, Marsaulté Bouarab K, Malouin F. 2011. Tomatidine inhibits replication of Staphylococcus aureus smallcolony variants in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 55:1937-1945. http://dx.doi.org/10.1128/AAC.01468-10.
27. Guay I, Chagnon F, Mitchell G, Bouarab K, Marsault E, Malouin F. 2012. Antibacterial spectrum and structure-activity relationship of tomatidine analogs. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, abstr F-1997.
28. Lamontagne Boulet M, Guay I, Rodrigue S, Jacques P-E, Brzezinski R, Bouarab K, Marsault E, Malouin F. 2015. Identification of mutations associated with a reduced susceptibility of Staphylococcus aureus smallcolony variants to tomatidine, abstr P0729. Abstr 25th Eur Congr Clin Microbiol Infect Dis.
29. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
30. Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot 66:571-591. http://dx.doi.org/10.1038/ja.2013.86.
31. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. 1995. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268:1899-1902. http://dx.doi.org/10.1126 /science.7604262.
32. - specific factors. Microbiology 155:712-723. http://dx.doi.org/10.1099/mic.0.022764-0.
33. Déziel E, Lépine F, Milot S, He J, Mindrinos MN, Tompkins RG, Rahme LG. 2004. Analysis of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines (HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell communication. Proc Natl Acad Sci U S A 101:1339-1344. http://dx.doi.org/10.1073/pnas.0307694100.
34. Lépine F, Milot S, Déziel E, He J, Rahme LG. 2004. Electrospray/mass spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs) produced by Pseudomonas aeruginosa. J Am Soc Mass Spectrom 15:862-869. http://dx.doi.org/10.1016/j.jasms.2004.02.012.
35. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci U S A 103:2833-2838. http://dx.doi.org/10.1073 /pnas.0511100103.
36. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
37. Dubern J, Diggle SP. 2008. Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas aeruginosa and other bacterial species. Mol Biosyst 4:882-888. http://dx.doi.org/10.1039/b803796p.
38. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B, Pulmonary Clinical Practice Guidelines Committee. 2013. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187:680-689. http://dx.doi.org/10.1164/rccm.201207-1160OE.
39. Bhatt JM. 2013. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 22:205-216. http://dx.doi.org/10.1183/09059180.00006512.
40. Barequet IS, Habot-Wilner Z, Mann O, Safrin M, Ohman DE, Kessler E, Rosner M. 2009. Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model. Graefes Arch Clin Exp Ophthalmol 247:913-917. http://dx.doi.org/10.1007/s00417-009-1061-2.
41. Sotirova AV, Spasova DI, Galabova DN, Karpenko E, Shulga A. 2008. Rhamnolipid-biosurfactant permeabilizing effects on Gram-positive and Gram-negative bacterial strains. Curr Microbiol 56:639-644. http://dx.doi.org/10.1007/s00284-008-9139-3.
42. Lightbown JW, Jackson FL. 1956. Inhibition of cytochrome systems of heart muscle and certain bacteria by the antagonists of dihydrostreptomycin: 2-alkyl-4-hydroxyquinoline N-oxides. Biochem J 63:130-137. http: //dx.doi.org/10.1042/bj0630130.
43. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, Bhuju S, O'Toole GA. 2015. Co-culture of Staphylococcus aureus with Pseudomonas aeruginosa drives S. aureus towards fermentative metabolism and reduced viability in a cystic fibrosis model. J Bacteriol 197:2252-2264. http://dx.doi.org/10.1128/JB.00059-15.
44. Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E, Proctor RA, Peters G. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 177:1023-1029. http://dx.doi.org/10.1086/515238.
45. Chagnon F, Guay I, Bonin M-A, Mitchell G, Bouarab K, Malouin F, Marsault E. 2014. Unraveling the structure-activity relationship of tomatidine, a steroid alkaloid with antibiotic properties against persistent forms of Staphylococcus aureus. Eur J Med Chem 80:605-620. http://dx.doi.org /10.1016/j.ejmech.2013.11.019.
46. Sadowska B, Bonar A, Von Eiff C, Proctor RA, Chmiela M, Rudnicka W, Rózálska B. 2002. Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol Med Microbiol 32:191-197. http://dx.doi.org/10.1111/j.1574-695X.2002.tb00553.x.
47. Kahl BC, Duebbers A, Lubritz G, Haeberle J, Koch HG, Ritzerfeld B, Reilly M, Harms E, Proctor RA, Herrmann M, Peters G. 2003. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 41:4424-4427. http://dx.doi.org/10.1128/JCM.41.9.4424-4427.2003.
48. Mitchell G, Malouin F. 2012. Outcome and prevention of Pseudomonas aeruginosa-Staphylococcus aureus interactions during pulmonary infections in cystic fibrosis, p 181-206. In Sriramulu D (ed), Cystic fibrosis. InTech, Rijeka, Croatia.
49. Barr HL, Halliday N, Cámara M, Barrett DA, Williams P, Forrester DL, Simms R, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Fogarty AW. 28 May 2015. Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis. Eur Respir J http://dx.doi.org/10.1183/09031936.00225214.
50. Novartis Pharmaceuticals Corporation. Tobi, tobramycin inhalation solution package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ. http://www.accessdata.fda.gov/drugsatfda-docs/label /2014/050753s016lbl.pdf.